Marker Therapeutics Announces Clinical Program Updates and
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical...
Source: globenewswire.com
Stay updated with breaking news from Cell Ready. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Strategic prioritization of clinical programs with focus on MT-601 in patients with lymphoma MultiTAA-specific T cell therapies demonstrate clinical...
Unaudited Pro Forma Condensed Consolidated Financial Information On June 26, 2023 , Marker Therapeutics, Inc. completed the previously announced transaction with Cell Ready,...